Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis

Area of Science:

• Health Economics
• Pharmaceutical Pricing
• Health Technology Assessment

Background:

• Economic evaluations increasingly use price-threshold analyses for value-based pricing.
• Standard analyses are inadequate for treatments with multiple indications.
• Pricing and reimbursement rules influence value-based price assessments.

Purpose of the Study:

• To examine how indication-specific pricing and reimbursement rules affect value-based price analyses.
• To model the strategic interactions between manufacturers and payers in multi-indication drug markets.

Main Methods:

• A two-stage game theory model between a therapy manufacturer and a payer.
• Analysis of indication-specific demand, manufacturer profit maximization, and payer willingness-to-pay thresholds.
• Consideration of game variants with differing constraints on pricing and reimbursement decisions.

Main Results:

• With fully flexible indication-specific pricing and reimbursement, the market simplifies to multiple single-indication analyses.
• When a single price is imposed with all-or-nothing reimbursement, the price becomes a weighted average, subsidizing less valuable indications.
• Single pricing with indication-specific coverage can lead to high prices and restricted access, or lower prices with broader access and consumer surplus.

Conclusions:

• Economic evaluations for multi-indication treatments must account for specific pricing and reimbursement regulations.
• The structure of pricing and reimbursement significantly influences treatment accessibility and overall market value.